AIP
BCLI

Ameritas Investment Partners’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Ameritas Investment Partners’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-157
Closed -$9K – 3064
2021
Q1 		$9K Hold
157
– – ﹤0.01% 2886
2020
Q4 		$11K Hold
157
– – ﹤0.01% 2735
2020
Q3 		$40K Hold
157
– – ﹤0.01% 1968
2020
Q2 		$26K Buy
+157
New +$16.9K ﹤0.01% 2195

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ameritas Investment Partners's BCLI Position: Q2 2021 in Review

Ameritas Investment Partners sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 157 shares — an estimated $9K sold.

Ameritas Investment Partners first reported a position in BCLI in Q2 2020 and held it in 4 quarters. The position peaked at $40K in Q3 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • Ameritas Investment Partners reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 157 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $9K.
  • Ameritas Investment Partners first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 4 quarters.
  • Ameritas Investment Partners's BRAINSTORM CELL THERAPUTC position peaked at $40K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.